Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2
Background: Talimogene laherparepvec (T-VEC) and interleukin-2 (IL-2) are both used in the intralesional treatment of melanoma skin metastases. T-VEC received regulatory approval from the European Medicines Agency and the U.S. Food and Drug Administration in 2015, while IL-2 has been used off-label...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251324035 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850263634404442112 |
|---|---|
| author | Markus Reitmajer Lena Nanz Nina Müller Ulrike Leiter Teresa Amaral Valentin Aebischer Lukas Flatz Andrea Forschner |
| author_facet | Markus Reitmajer Lena Nanz Nina Müller Ulrike Leiter Teresa Amaral Valentin Aebischer Lukas Flatz Andrea Forschner |
| author_sort | Markus Reitmajer |
| collection | DOAJ |
| description | Background: Talimogene laherparepvec (T-VEC) and interleukin-2 (IL-2) are both used in the intralesional treatment of melanoma skin metastases. T-VEC received regulatory approval from the European Medicines Agency and the U.S. Food and Drug Administration in 2015, while IL-2 has been used off-label for this purpose for many years. Despite their use in clinical practice, there is a lack of comparative data on the efficacy and safety of these treatments. Objectives: This retrospective study aimed to compare the efficacy and safety of intralesional T-VEC and IL-2 in non-resectable stage III patients with melanoma treated at a single center between January 2016 and September 2024. Methods: We identified eligible patients using the Central Malignant Melanoma Registry and the local University Hospital Pharmacy database. Overall survival (OS) and progression-free survival (PFS) were calculated. Furthermore, best response rates and occurrence of adverse events (AEs) were compared between the T-VEC and the IL-2 group. Concomitant systemic treatment was allowed. Results: A total of 62 patients were included, with 37 receiving T-VEC and 25 receiving IL-2 as first-line therapy. Ten patients received both therapies subsequently. The median PFS for the cohort was 5.0 months, and the median OS was 34.0 months. No significant differences in PFS ( p = 0.790), OS ( p = 0.894), or best response rates ( p = 0.468) were found between groups. Common AEs included local injection site reactions and fever, with no severe events leading to discontinuation by a physician. Conclusion: No significant differences in PFS, OS, or best response rates were observed between IL-2 and T-VEC treatments. The choice of therapy may be influenced by factors such as availability, physician preference, and patient-specific considerations. |
| format | Article |
| id | doaj-art-9aaffe5fe6b84049a1373d242e3d3bac |
| institution | OA Journals |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-9aaffe5fe6b84049a1373d242e3d3bac2025-08-20T01:54:55ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-03-011710.1177/17588359251324035Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2Markus ReitmajerLena NanzNina MüllerUlrike LeiterTeresa AmaralValentin AebischerLukas FlatzAndrea ForschnerBackground: Talimogene laherparepvec (T-VEC) and interleukin-2 (IL-2) are both used in the intralesional treatment of melanoma skin metastases. T-VEC received regulatory approval from the European Medicines Agency and the U.S. Food and Drug Administration in 2015, while IL-2 has been used off-label for this purpose for many years. Despite their use in clinical practice, there is a lack of comparative data on the efficacy and safety of these treatments. Objectives: This retrospective study aimed to compare the efficacy and safety of intralesional T-VEC and IL-2 in non-resectable stage III patients with melanoma treated at a single center between January 2016 and September 2024. Methods: We identified eligible patients using the Central Malignant Melanoma Registry and the local University Hospital Pharmacy database. Overall survival (OS) and progression-free survival (PFS) were calculated. Furthermore, best response rates and occurrence of adverse events (AEs) were compared between the T-VEC and the IL-2 group. Concomitant systemic treatment was allowed. Results: A total of 62 patients were included, with 37 receiving T-VEC and 25 receiving IL-2 as first-line therapy. Ten patients received both therapies subsequently. The median PFS for the cohort was 5.0 months, and the median OS was 34.0 months. No significant differences in PFS ( p = 0.790), OS ( p = 0.894), or best response rates ( p = 0.468) were found between groups. Common AEs included local injection site reactions and fever, with no severe events leading to discontinuation by a physician. Conclusion: No significant differences in PFS, OS, or best response rates were observed between IL-2 and T-VEC treatments. The choice of therapy may be influenced by factors such as availability, physician preference, and patient-specific considerations.https://doi.org/10.1177/17588359251324035 |
| spellingShingle | Markus Reitmajer Lena Nanz Nina Müller Ulrike Leiter Teresa Amaral Valentin Aebischer Lukas Flatz Andrea Forschner Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2 Therapeutic Advances in Medical Oncology |
| title | Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2 |
| title_full | Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2 |
| title_fullStr | Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2 |
| title_full_unstemmed | Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2 |
| title_short | Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2 |
| title_sort | comparative real world outcomes of stage iii melanoma patients treated with talimogene laherparepvec or interleukin 2 |
| url | https://doi.org/10.1177/17588359251324035 |
| work_keys_str_mv | AT markusreitmajer comparativerealworldoutcomesofstageiiimelanomapatientstreatedwithtalimogenelaherparepvecorinterleukin2 AT lenananz comparativerealworldoutcomesofstageiiimelanomapatientstreatedwithtalimogenelaherparepvecorinterleukin2 AT ninamuller comparativerealworldoutcomesofstageiiimelanomapatientstreatedwithtalimogenelaherparepvecorinterleukin2 AT ulrikeleiter comparativerealworldoutcomesofstageiiimelanomapatientstreatedwithtalimogenelaherparepvecorinterleukin2 AT teresaamaral comparativerealworldoutcomesofstageiiimelanomapatientstreatedwithtalimogenelaherparepvecorinterleukin2 AT valentinaebischer comparativerealworldoutcomesofstageiiimelanomapatientstreatedwithtalimogenelaherparepvecorinterleukin2 AT lukasflatz comparativerealworldoutcomesofstageiiimelanomapatientstreatedwithtalimogenelaherparepvecorinterleukin2 AT andreaforschner comparativerealworldoutcomesofstageiiimelanomapatientstreatedwithtalimogenelaherparepvecorinterleukin2 |